Cencora, INC. (COR) — SEC Filings

Overview

Cencora, INC. (COR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 15, 2025: On December 12, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report detailing the issuance of $1.5 billion in aggregate principal amount of senior notes. These notes include $750 million of 2.875% Senior Notes due 2028 and $750 million of 3.625% Senior Notes due 2032. The filin

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 47 neutral, 1 mixed. The dominant filing sentiment for Cencora, INC. is neutral.

Filing Type Overview

Cencora, INC. (COR) has filed 31 8-K, 2 10-K, 6 10-Q, 1 DEFA14A, 3 SC 13G/A, 3 SC 13D/A, 2 8-K/A, 1 SC 13G, 1 DEF 14A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• Cencora Issues $1.5B in Senior Notes — 8-K · Dec 15, 2025 Risk: medium
  On December 12, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report detailing the issuance of $1.5 billion in aggregate principal amount o
• Cencora Eyes 8.4% Pharma Growth, Boosts Generics & Global Reach — 10-K · Nov 25, 2025 Risk: medium
  Cencora, Inc. (COR) filed its 10-K for the fiscal year ended September 30, 2025, highlighting its position as a major global pharmaceutical sourcing and distrib
• Cencora, Inc. Files 8-K on Financials — 8-K · Nov 5, 2025 Risk: low
  Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing als
• Cencora Enters Material Definitive Agreement for Senior Notes — 8-K · Sep 9, 2025 Risk: medium
  On September 5, 2025, Cencora, Inc. entered into a material definitive agreement related to its 2.875% Senior Notes due 2028 and 3.625% Senior Notes due 2032. T
• Cencora Prices $1.5B Senior Notes Offering — 8-K · Sep 3, 2025 Risk: medium
  On September 3, 2025, Cencora, Inc. filed an 8-K report detailing the issuance of $1.5 billion in aggregate principal amount of senior notes. These notes consis
• Cencora, Inc. Files 8-K: Director Changes & Executive Comp — 8-K · Aug 27, 2025 Risk: low
  Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K on August 27, 2025, reporting on the departure of directors, election of new directors, appointment
• Cencora's Q3 Revenue Jumps to $210B, Net Income Up 15% — 10-Q · Aug 6, 2025 Risk: medium
  Cencora, Inc. reported robust financial performance for the nine months ended June 30, 2025, with revenue reaching $210.0 billion, a significant increase from $
• Cencora, Inc. Reports Material Definitive Agreement — 8-K · Jul 3, 2025 Risk: medium
  On June 30, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) entered into a material definitive agreement related to financial obligations. The filing indi
• Cencora, Inc. Enters New Agreements, Terminates Others — 8-K · Jun 6, 2025 Risk: medium
  On June 4, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) entered into a material definitive agreement and terminated another. The company also created a
• Cencora Appoints New Officers, Directors; Updates Compensation — 8-K · May 28, 2025 Risk: low
  Cencora, Inc. announced on May 21, 2025, the appointment of new officers and directors, along with updates to compensatory arrangements. The company also disclo
• Cencora Files 8-K on Material Agreement & Financial Obligation — 8-K · May 22, 2025 Risk: medium
  On May 22, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report detailing a material definitive agreement and a direct financial obligation
• Cencora, Inc. Files 8-K Report — 8-K · May 19, 2025 Risk: low
  On May 15, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report. The filing primarily concerns other events and financial statements/exhibi
• Cencora, Inc. Files Q2 2025 10-Q Report — 10-Q · May 7, 2025 Risk: low
  Cencora, Inc. filed its 10-Q for the period ending March 31, 2025. The filing covers the company's financial performance and operations. Specific financial figu
• Cencora, Inc. Files 8-K for Regulation FD Disclosure — 8-K · Mar 10, 2025 Risk: low
  On March 10, 2025, Cencora, Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure, indicating that material non-
• Cencora, Inc. Files 8-K: Material Definitive Agreement — 8-K · Feb 10, 2025 Risk: medium
  On February 6, 2025, Cencora, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhib
• Cencora, Inc. Files Q1 2025 10-Q Report — 10-Q · Feb 5, 2025 Risk: low
  Cencora, Inc. filed its 10-Q report for the period ending December 31, 2024. The company, formerly known as AmerisourceBergen Corp, operates in the wholesale dr
• Cencora Inc. Files Proxy Materials — DEFA14A · Jan 23, 2025 Risk: low
  Cencora, Inc. (formerly AmerisourceBergen Corp) filed a Definitive Additional Materials proxy statement on January 23, 2025. This filing relates to the company'
• Cencora, Inc. Files 8-K: Board and Executive Changes — 8-K · Jan 22, 2025 Risk: medium
  On January 22, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report detailing changes in its board of directors and executive compensation.
• Cencora, Inc. Files 8-K on Asset Acquisition/Disposition — 8-K · Jan 2, 2025 Risk: medium
  On January 2, 2025, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report detailing the completion of an acquisition or disposition of assets. The
• Cencora, Inc. Files 8-K for Material Definitive Agreement — 8-K · Dec 10, 2024 Risk: medium
  On December 9, 2024, Cencora, Inc. entered into a material definitive agreement related to a direct financial obligation. The company, formerly known as Ameriso
• Cencora, Inc. Files 8-K Report — 8-K · Dec 4, 2024 Risk: low
  On December 2, 2024, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other even
• Cencora, Inc. Files 8-K for Material Definitive Agreement — 8-K · Nov 27, 2024 Risk: medium
  On November 26, 2024, Cencora, Inc. entered into a material definitive agreement related to a direct financial obligation. The company, formerly known as Ameris
• Cencora, Inc. Files 2024 10-K Report — 10-K · Nov 26, 2024 Risk: medium
  Cencora, Inc. (formerly AmerisourceBergen Corp) filed its 2024 10-K report for the fiscal year ending September 30, 2024. The company, a wholesale distributor o
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Cencora, Inc. Files 8-K Report — 8-K · Nov 8, 2024 Risk: low
  On November 5, 2024, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other even
• Cencora, Inc. Files 8-K on Financials — 8-K · Nov 6, 2024 Risk: low
  On November 6, 2024, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report. The filing primarily concerns the company's results of operations and
• Cencora, Inc. Enters Material Definitive Agreement — 8-K · Oct 15, 2024 Risk: medium
  On October 9, 2024, Cencora, Inc. entered into a material definitive agreement related to a direct financial obligation. The company, formerly known as Amerisou
• Cencora, Inc. Files 8-K Report — 8-K · Sep 5, 2024 Risk: low
  On September 5, 2024, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report. The filing indicates no specific material events or disclosures beyon
• WBA Amends Cencora Stake Filing — SC 13D/A · Aug 20, 2024 Risk: low
  Walgreens Boots Alliance, Inc. (WBA) has filed an amendment (No. 18) to its Schedule 13D concerning Cencora, Inc. (COR). The filing, dated August 20, 2024, indi
• Cencora, Inc. Files 8-K: Material Agreement & Officer Changes — 8-K · Aug 16, 2024 Risk: medium
  Cencora, Inc. (formerly AmerisourceBergen Corp) announced on August 13, 2024, a material definitive agreement and changes related to its board and officers. The
• Cencora Appoints New CFO, Robert P. Long — 8-K · Aug 15, 2024 Risk: medium
  On August 13, 2024, Cencora, Inc. announced the appointment of Robert P. Long as Executive Vice President and Chief Financial Officer, effective August 19, 2024
• WBA Amends Cencora Stake Filing — SC 13D/A · Aug 5, 2024 Risk: medium
  Walgreens Boots Alliance, Inc. (WBA) filed an amendment (17) to its Schedule 13D on August 5, 2024, regarding its holdings in Cencora, Inc. (formerly Amerisourc
• Cencora, Inc. Files 8-K Report — 8-K · Aug 5, 2024 Risk: low
  On August 1, 2024, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report detailing a material definitive agreement. The filing also includes other
• Cencora, Inc. Files Q3 2024 10-Q Report — 10-Q · Jul 31, 2024 Risk: low
  Cencora, Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the third quarter of their fiscal year. Key financial data and business oper
• Cencora, Inc. Files 8-K Amendment — 8-K/A · Jul 31, 2024 Risk: medium
  Cencora, Inc. filed an amendment (8-K/A) on July 31, 2024, to a report originally filed on February 21, 2024. This amendment pertains to Item 1.05, which relate
• Cencora, Inc. Enters Material Definitive Agreement — 8-K · May 24, 2024 Risk: medium
  On May 22, 2024, Cencora, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement or any associated do
• Cencora Names New Board Chair, Adds Directors — 8-K · May 3, 2024 Risk: low
  On April 30, 2024, Cencora, Inc. announced changes to its Board of Directors, including the election of two new independent directors, Steven A. Denning and Dr.
• Cencora, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 1, 2024 Risk: low
  Cencora, Inc. (COR) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Cencora, Inc. (formerly AmerisourceBergen Corp) filed a 10-Q report for the per
• Cencora, Inc. Files 8-K for Material Definitive Agreement — 8-K · Apr 23, 2024 Risk: medium
  On April 17, 2024, Cencora, Inc. entered into a Material Definitive Agreement related to a direct financial obligation. The filing details the creation of this
• Cencora, Inc. Amends Filing for Director Changes — 8-K/A · Mar 15, 2024 Risk: low
  Cencora, Inc. filed an amendment (8-K/A) on March 15, 2024, to a previous filing from March 11, 2024. This amendment primarily concerns the departure of a direc
• Cencora, Inc. Files 8-K: Board Changes & Executive Compensation Updates — 8-K · Mar 12, 2024 Risk: low
  On March 11, 2024, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report detailing changes in its board of directors and executive compensation ar
• Cencora Files 8-K; Event Date Feb 21, Details Not Provided — 8-K · Feb 27, 2024 Risk: low
  Cencora, Inc. filed an 8-K on February 27, 2024, reporting an earliest event date of February 21, 2024. The filing identifies the company, formerly known as AME
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Walgreens Updates Cencora Stake: SC 13D/A Filed Feb 7, 2024 — SC 13D/A · Feb 9, 2024 Risk: medium
  Walgreens Boots Alliance, Inc. (WBA) filed an amendment to its Schedule 13D, indicating a significant change in its ownership stake in Cencora, Inc. (formerly A
• Cencora Files 8-K on Material Definitive Agreement — 8-K · Feb 9, 2024 Risk: medium
  Cencora, Inc. (formerly AmerisourceBergen Corp.) filed an 8-K on February 9, 2024, reporting an event that occurred on February 7, 2024. This filing indicates a
• Cencora Files Routine 8-K for Feb 5 Event; No New Material Info — 8-K · Feb 7, 2024
  Cencora, Inc. filed an 8-K on February 7, 2024, reporting an event that occurred on February 5, 2024. This filing is a routine update, primarily serving to sati
• Cencora, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Jan 31, 2024 Risk: low
  Cencora, Inc. (COR) filed a Quarterly Report (10-Q) with the SEC on January 31, 2024. Cencora, Inc. (COR) filed a 10-Q report for the period ending December 31,
• Cencora, Inc. Files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · Jan 29, 2024 Risk: medium
  Cencora, Inc. (COR) filed a Proxy Statement (DEF 14A) with the SEC on January 29, 2024. Cencora, formerly AmerisourceBergen, rebranded in fiscal 2023 to reflect
• BlackRock Amends Cencora Stake, Maintains Passive Investment — SC 13G/A · Jan 24, 2024
  BlackRock Inc. has updated its ownership stake in Cencora, Inc. (formerly AmerisourceBergen Corp.) as of December 31, 2023, filing an Amendment No. 15 to its Sc

Risk Profile

Risk Assessment: Of COR's 45 recent filings, 0 were flagged as high-risk, 24 as medium-risk, and 21 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Cencora, INC.'s most recent 10-K filing (Nov 25, 2025):

• Revenue: $37,887,695,618

Key Executives

• Lanesha Minnix
• Robert P. Long
• Steven A. Denning
• Dr. Lisa M. Su
• Matthew D'Ambrosio
• Lillian Tsu
• Werner Baumann
• Lauren Tyler

Industry Context

Cencora operates in the global pharmaceutical sourcing and distribution services sector. The U.S. pharmaceutical market is projected to grow at an 8.4% CAGR from 2024-2029, driven by an aging population and new drug innovations like biotechnology and gene therapy. The company benefits from the significant volume and higher gross margins associated with generic and biosimilar pharmaceuticals, which constitute 90% of U.S. prescriptions.

Top Tags

material-agreement (10) · corporate-governance (8) · amendment (6) · financial-obligation (5) · 10-Q (5) · financing (4) · corporate-action (4) · debt (3) · executive-compensation (3) · sec-filing (3)

Key Numbers

• Senior Notes Issued: $1.5B — Total aggregate principal amount of new debt offering.
• Interest Rate (2028 Notes): 2.875% — Coupon rate for the $750 million Senior Notes due 2028.
• Interest Rate (2032 Notes): 3.625% — Coupon rate for the $750 million Senior Notes due 2032.
• Aggregate market value of voting stock held by non-affiliates: $37,887,695,618 — As of March 31, 2025, indicating significant market capitalization.
• Shares of common stock outstanding: 193,993,444 — As of October 31, 2025, providing insight into share count.
• Projected compound annual growth rate for U.S. pharmaceutical sales: 8.4% — From 2024 through 2029, indicating strong industry tailwinds for Cencora.
• Estimated number of individuals aged 65 and over in the U.S.: 71 million — By 2029, highlighting the aging population as a key growth driver for pharmaceutical demand.
• Approximate percentage of prescription volume accounted for by generic pharmaceuticals in the U.S.: 90% — Generics offer Cencora greater gross profit margin opportunities despite lower prices.
• Percentage of overall healthcare costs accounted for by pharmaceuticals: 9% — According to CMS, indicating the relative impact of drug therapy on healthcare expenditures.
• Senior Notes Interest Rate: 2.875% — Interest rate on notes due 2028
• 2032 Senior Notes: $750M — Principal amount of the 3.625% senior notes due 2032.
• 2028 Senior Notes: $750M — Principal amount of the 2.875% senior notes due 2028.
• Revenue: $210.0B — Increased from $190.0B in prior year, a 10.5% increase.
• Net Income: $1.5B — Increased from $1.3B in prior year, a 15.4% increase.
• Total Assets: $65.0B — Increased from $62.0B at September 30, 2024.

Forward-Looking Statements

• {"claim":"Walgreens Boots Alliance may continue to adjust its stake in Cencora, potentially leading to further filings.","entity":"Walgreens Boots Alliance, Inc.","targetDate":"2024-12-31","confidence":"medium"}
• {"claim":"Cencora will release more details about the 'Material Definitive Agreement' in a subsequent filing or press release.","entity":"Cencora, Inc.","targetDate":"2024-03-01","confidence":"high"}
• {"claim":"The stock price of Cencora (COR) will experience volatility as investors await details of the agreement.","entity":"COR","targetDate":"2024-02-23","confidence":"medium"}

Related Companies

MCK · CAH · ABC · WBA

Frequently Asked Questions